series-a
Stage
2020
Founded
1
Investors
About
Lilac Therapeutics is a clinical-stage company developing LLX-424, a small molecule glycolate oxidase inhibitor designed to prevent recurrent calcium oxalate kidney stones by reducing urinary oxalate levels.
Explore Lilac Therapeutics's full profile on Brouky
Funding rounds, investor list, and risk signals — unlock with a subscription.